RxDoctor Payments DataLook up a doctor →

Al-Ola Abdallah, MD

Internal Medicine · Tulsa, OKNPI 1386837151

Payments from drug & device makers

$10,149,519in general payments, 2019–2025

Across 673 payments — averaging $15,081 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2.6M
  • Seagen Inc.$1.9M
  • Bristol Myers Squibb$1.8M
  • E.r. Squibb & Sons, L.L.C.$1.8M
  • Amgen$1.5M
  • Sanofi US Services Inc.$270K
  • plus $253K from 10 others
$1,285in research payments, 2019–2025

Across 2 payments — averaging $642.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$1K
  • AbbVie$35

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,149,519 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$146,511
Medicare patients
406
Services billed
2,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →